Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: VGX-1027 To Undergo Additional Testing For RA
D Scott Cunningham MD, PhD, MDLinx Rheumatology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Longterm visual prognosis of patients with Ocular Adamantiades-Behçet's disease treated with interferon &alpha 2a
Journal of Rheumatology, 04/16/08
Print     Email This Article     Save in My Library   Free Abstract
Krause L et al. - Longterm remission of ocular inflammation can be achieved with the combination of IFN- &alpha and low-dose corticosteroids.

Methods
  • Longterm effects of IFN &alpha 2a in a case series of 45 pts with ocular involvement was examined
  • 45 pts with ocular involvement in ABD were treated with IFN- &alpha (3 ´ 6-9 Mio IU/wk)
  • In the initial acute phase, pts additionally received short-term corticosteroids, tapered to a maintenance dose within 2 wks
  • IFN- &alpha -2a was administered as longterm therapy with a mean duration of 30 mos

Results
  • IFN- &alpha -2a/prednisolone treatment was effective against vasculitis, optic nerve neuropathy, and iritis
  • 64 eyes had no recurrence under therapy
  • To date, recurrences have been seen in 26 eyes under IFN- &alpha treatment
  • Flu-like symptoms were recorded in nearly all patients (n=43)
  • Side effects were dose-dependent reversible thrombocytopenia (n=1), psychosis (n=3), depression (n=13), thyroiditis (n=1), and reversible diffuse alopecia (n=7)
  • 92% of all eyes showed stable or improved visual acuity in longterm f/u

Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.